Merck
MRK
#50
Rank
โ‚ฌ260.51 B
Marketcap
105,48ย โ‚ฌ
Share price
5.64%
Change (1 day)
55.65%
Change (1 year)

P/E ratio for Merck (MRK)

P/E ratio as of May 2026 (TTM): 34.3

According to Merck's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 34.2629. At the end of 2025 the company had a P/E ratio of 14.4.

P/E ratio history for Merck from 2001 to 2026

PE ratio at the end of each year

Year P/E ratio Change
202514.4-0.02%
202414.4-97.87%
20236793674.95%
202218.034.71%
202113.4-44.9%
202024.227.46%
201919.0-25.19%
201825.4-44.27%
201745.6116.87%
201621.0-11.64%
201523.8152.83%
20149.42-58.32%
201322.686.02%
201212.16.11%
201111.4

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
26.8-21.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
21.7-36.62%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
19.8-42.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
24.2-29.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
37.7 10.14%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
23.4-31.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
17.3-49.37%๐Ÿ‡ซ๐Ÿ‡ท France
Bristol-Myers Squibb
BMY
16.8-51.11%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
13.2-61.36%๐Ÿ‡ฌ๐Ÿ‡ง UK
Teva Pharmaceutical Industries
TEVA
24.9-27.27%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.